CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 209 enrolled
Drug / intervention
sirolimusdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00484094
NCT00484094N/ACompleted

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Rapamune

Pfizer·observational·Posted Jun 8, 2007·Updated Jan 16, 2017

In Brief

An observational study evaluating sirolimus for Kidney Transplantation. Completed, enrolled 209 participants across 11 sites.

Detailed Summary

To provide safety and effectiveness information for Rapamune during the post-marketing period as required by Korea Food and Drug Administration (KFDA) regulations in order to identify any potential drug related treatment factors in the Korean population, such as: 1. Unknown adverse reactions, especially serious adverse reactions 2. To assess the incidence of adverse reactions under the routine drug uses 3. Factors that may affect the safety of the drug (e.g., proteinuria) 4. Factors that may affect the effectiveness of the drug

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 8, 2007
Enrollment StartJul 1, 2011
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 19.1 years ago

Interventions

sirolimusdrug

Dosage and treatment duration will be decided by physician's discretion considering patient's clinical situations